Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Baricitinib in Pediatric Patients With Moderate to Severe Atopic Dermatitis
NCT03952559Phase 3Completed
- Sponsor
- Eli Lilly and Company
- Start
- May 2019
- Primary completion
- Apr 2022
- Modality
- Recombinant Proteins and Enzymes, Small Molecules, Antibody-Based Therapeutics
- Countries
- 17
01
Overview
Phase 3, randomised, double-blind trial of baricitinib in atopic dermatitis (AD) (5 arms), sponsored by Eli Lilly and Company. Primary endpoints: Percentage of Participants Achieving Investigator's Global Assessment (IGA) of 0 or 1 With a ≥2 Point Improvement at 16 weeks, Maximum Observed Drug Concentration at Steady State at 4 hours and 1 more. Started May 2019; status: completed.
02
Drugs
baricitinib
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on NCT03952559.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03952559.